Clinical Observation of Recombinant Human Interleukin 11 Derivative in the Treatment of Malignant Tumor Chemotherapy-induced Thrombocytopenia

Li Yuq

Abstract:Objective To investigate the efficacy and safety of recombinant human interleukin 11 derivative(Baijieyi) in treatment of malignant tumor chemotherapy-induced thrombocytopenia(CIT) compared with rh IL-11(Jijufen). Methods 50 cases of malignant tumor patients whose PLT 50 × 109/L were divided into Baijieyi group and Jijufen group according to self-control study. Baijieyi group was given Baijieyi(1.5 mg) after the first chemotherapy treatment, and given Jijufen(3 mg) after the second chemotherapy treatment. The medication order of Jijufen group was opposite to Baijieyi group. When patients' PLT 100 × 109/L, the medication was stopped. The treatment effect,changes of peripheral blood platelets and incidence of adverse reactions were compared. Results The total effective rate of two groups had no statistical difference(P 0.05). The lasting days of PLT 20 × 109/L and time of PLT returned to normal level in Baijieyi group were shorter than those in Jijufen group, with statistical difference(P 0.05); the minimum value of PLT and lasting days of PLT 50 × 109/L in two groups had no statistical difference(P 0.05). The main adverse reactions included hypodynamia, fever, headache, pain at injection site,muscle and joint pain, palpitation and facial limbs swelling, and all the adverse reactions were resolved spontaneously after stopping medication, the incidence of adverse reactions of two groups had no statistical difference(P 0.05). Conclusions Comparing with rh IL-11,rh IL-11 derivative can effectively shorten the lasting days of PLT 20 × 109/L and time of PLT returned to normal level, without increasing the incidence of adverse reactions, which is an effective and safety pharmaceutical in the treatment of malignant tumor CIT.

Medicine